LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
(Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the
treatment of severe genetic rare diseases, today announced the closing of its previously announced underwritten public offering of
6,612,500 ordinary shares at a price to the public of $15.75 per share. The closing included the full exercise of
the underwriters’ option to purchase 862,500 additional ordinary shares at the public offering price, less underwriting discounts
and commissions. Gross proceeds from the offering totaled approximately $104.1 million, before deducting underwriting
discounts and commissions and offering expenses.
Citigroup, Evercore ISI and RBC Capital Markets acted as joint bookrunners for the offering. H.C.
Wainwright & Co. and Chardan acted as co-managers for the offering. Kempen & Co acted as the Company’s European financial
advisor in relation to this offering.
A shelf registration statement relating to the offered ordinary shares was filed with the Securities and
Exchange Commission (SEC) on October 2, 2015, which was declared effective on October 19, 2015. A prospectus
supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the
SEC's website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating
to the offering may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd
Street, 36th Floor, New York, NY 10055, or by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com; or RBC Capital Markets, LLC, Attention: Equity Syndicate, 200
Vesey Street, 8th Floor, New York, NY 10281, or by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities
nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe
genetic rare diseases such as Leber’s congenital amaurosis 10, dystrophic epidermolysis bullosa and cystic fibrosis. Based on our
unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar
expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to
management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements
about ProQR’s business and efforts to develop RNA medicines. These forward-looking statements involve risks and uncertainties, many
of which are beyond ProQR’s control. Applicable risks also include those that are included in ProQR’s prospectus supplement and
accompanying prospectus filed with the SEC for the offering, including the documents incorporated by reference therein, which
include ProQR’s Annual Report on Form 20-F for the year ended December 31, 2017, and any subsequent SEC filings. Given these risks,
uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new information becomes available in the future, except as required
by law.
ProQR Therapeutics N.V.:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
ir@proqr.com
